Know Cancer

forgot password

A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer

Phase 2
18 Years
65 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer

This is an open-label Phase 2 neoadjuvant study for patients with histologically confirmed,
HER-2 positive operable breast cancer. All patients will receive 18 weeks of neoadjuvant

The trial has an initial 2 week "biomarker lead in" phase. During this two week phase
patients will either receive Trastuzumab alone or Trastuzumab + Everolimus. This two week
lead in phase will be randomized open label. The rest of the 16 weeks of the neoadjuvant
trial treatment is non randomized open label.

For the first two weeks of neoadjuvant treatment the eligible subjects will be randomly
assigned to either receive or not receive Everolimus. This assignment will be accomplished
by a previously prepared schedule (maintained by the investigational pharmacy), such that
investigators are unaware of assignment until after the subject has been enrolled on the
study and received assignment of Everolimus or not.

Inclusion Criteria:

- Female ≥ 18 to 65 years of age

- Histologically proven stage I, II or III adenocarcinoma of breast

- Candidate for adjuvant chemotherapy and Trastuzumab (Tumor size > 1 cm, T2, T3, T4
and/or clinical N1 or N2)

- HER-2 positive breast cancer (IHC 3+ or FISH ratio of > 2.0)

- ECOG Performance status 0-2

- No prior chemotherapy or HER-2 targeted therapy for breast cancer

- Not pregnant or breast feeding or adult of reproductive potential using effective
birth control methods. If barrier contraceptives are used, these must be continued
throughout trial by both sexes. Hormonal contraceptives not acceptable as a sole
method of contraception. Women of childbearing potential must have negative urine or
serum pregnancy test within 7 days before administration of RAD001

- Adequate bone marrow function: ANC > 1500/mm3, platelet count > 100,000/mm3, and
hemoglobin > 11 g/dL

- Adequate kidney function: serum creatinine of < 1.5mg/dl and/or creatinine
clearance of > 60 mL/min

- Adequate hepatic function: transaminase < 2 x upper limit of normal and total
bilirubin < 1.5 mg/dL.

- INR ≤2.0 and PTT 1.5 X the upper limit of institution normal range. Oral
anticoagulants, eg,warfarin are CYP2C9 substrates and as such, no interaction with
RAD001 is expected. Anticoagulation with Coumadin allowed if target INR is ≤2.0 and
stable for > 2 weeks. Anticoagulation with LMWH is allowed.

- Must sign informed consent

- Pretreatment lab values for CBC and CMP performed within 14 days of registration
and other baseline studies within 30 days.

- Will have baseline mammogram, bone scan, CT chest and abdomen within 60 days of

- Adequate cardiac function (Cardiac ejection fraction ≥ 50% as measured by
echocardiogram or MUGA scan).

- Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤
2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, patient can
only be included after initiation of appropriate lipid lowering medication.

Exclusion Criteria:

- Prior HER-2 targeted therapy for breast cancer

- Metastatic disease

- Uncontrolled intercurrent illness including but not limited to, ongoing or active
infection requiring parenteral antibiotics or psychiatric illness/social situations
that would limit compliance with study requirements.

- GI tract disease resulting in inability to take oral medication, malabsorption
syndrome, a requirement for IV alimentation, prior surgical procedures affecting
absorption, uncontrolled inflammatory GI disease eg, Crohn's, ulcerative colitis).

- Current active hepatic or biliary disease (exception of patients with Gilbert's
syndrome, asymptomatic gallstones)

- Renal function as measured by creatinine clearance <30ml/min (ratio to norm <0.1)

- Pregnant

- Inflammatory breast cancer

- Active cardiac disease, defined as:

- History of uncontrolled or symptomatic angina

- History of arrhythmias requiring medications, or clinically significant, with
exception of asymptomatic atrial fibrillation requiring anticoagulation

- Myocardial infarction < 6 months from study entry

- Uncontrolled or symptomatic congestive heart failure

- Any other cardiac condition, which in opinion of treating physician, would make
this protocol unreasonably hazardous for the patient

- History of another primary cancer, with the exception of:

- curatively resected nonmelanomatous skin cancer

- curatively treated cervical carcinoma in-situ

- other primary solid tumor curatively resected,treated with no known active
disease present and no treatment administered for the last 3 years.

- Life expectancy of < 2 months

- Receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent. Topical or inhaled corticosteroids are allowed.

- Should not receive immunization with attenuated live vaccines within 1 week of study
entry or during study period

- Severely impaired lung function as defined as spirometry and DLCO that is 50% of
the normal predicted value and/or 02 saturation that is 88% or less at rest on
room air

- Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN

- Active (acute or chronic) or uncontrolled severe infections

- Known history of HIV seropositivity

- Active, bleeding diathesis

- Patients who have received prior treatment with an mTOR inhibitor (Sirolimus,
Temsirolimus, Everolimus).

- Known hypersensitivity to RAD001 (Everolimus) or other rapamycins (Sirolimus,
Temsirolimus) or to its excipients

- Active Hepatitis B or C infection

- > 65 years of age

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

assess complete response rate

Outcome Description:

To assess the pathological complete response rate (pCR) with of 4 cycles of neoadjuvant Herceptin plus Paclitaxel and Everolimus in patients with operable HER-2 positive breast cancer.

Outcome Time Frame:

5 months

Safety Issue:


Principal Investigator

Priyanka Sharma, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Kansas


United States: Food and Drug Administration

Study ID:




Start Date:

July 2010

Completion Date:

March 2012

Related Keywords:

  • Breast Cancer
  • breast cancer
  • HER2 positive
  • Phase II
  • RAD001
  • paclitaxel
  • trastuzumab
  • everolimus
  • Breast Neoplasms